Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
CareDx Inc ha un obiettivo di prezzo di consenso pari a $25.38, stabilito in base alle ultime valutazioni degli analisti di 10. Le ultime 3 valutazioni degli analisti sono state rilasciate da BTIG, BTIG y Wells Fargo il septiembre 23, 2025, septiembre 12, 2025 y agosto 8, 2025. Con un obiettivo di prezzo medio di $19.33 tra le BTIG, BTIG y Wells Fargo, c'è un implicito 26.78% upside per CareDx Inc da queste valutazioni degli analisti.
1calculado a partir de las calificaciones de los analistas
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
09/23/2025 | 44.26% | BTIG | $22 → $22 | Reiterates | Buy → Buy | |||
09/12/2025 | 44.26% | BTIG | $22 → $22 | Reiterates | Buy → Buy | |||
08/26/2025 | — | William Blair | — | Initiates | → Market Perform | |||
08/08/2025 | -8.2% | Wells Fargo | $19 → $14 | Maintains | Equal-Weight | |||
07/18/2025 | 70.49% | Craig-Hallum | $40 → $26 | Maintains | Buy | |||
05/05/2025 | 162.3% | Stephens & Co. | $40 → $40 | Reiterates | Overweight → Overweight | |||
05/05/2025 | 63.93% | HC Wainwright & Co. | $25 → $25 | Reiterates | Neutral → Neutral | |||
04/17/2025 | 70.49% | Goldman Sachs | $34 → $26 | Maintains | Buy | |||
03/03/2025 | 63.93% | HC Wainwright & Co. | $26 → $25 | Maintains | Neutral | |||
02/27/2025 | 162.3% | Stephens & Co. | $40 → $40 | Reiterates | Overweight → Overweight | |||
01/15/2025 | 57.38% | Wells Fargo | $28 → $24 | Upgrade | Underweight → Equal-Weight | |||
01/14/2025 | 70.49% | HC Wainwright & Co. | $26 → $26 | Reiterates | Neutral → Neutral | |||
11/05/2024 | 129.51% | BTIG | $40 → $35 | Maintains | Buy | |||
10/22/2024 | — | HC Wainwright & Co. | — | Reiterates | → Neutral | |||
10/16/2024 | 129.51% | Goldman Sachs | $26 → $35 | Maintains | Buy | |||
08/27/2024 | 83.61% | Wells Fargo | → $28 | Initiates | → Underweight | |||
08/19/2024 | 162.3% | BTIG | → $40 | Upgrade | Neutral → Buy | |||
08/01/2024 | 70.49% | Goldman Sachs | $16 → $26 | Maintains | Buy | |||
08/01/2024 | 109.84% | Craig-Hallum | $22 → $32 | Maintains | Buy | |||
08/01/2024 | — | HC Wainwright & Co. | — | Reiterates | → Neutral | |||
07/17/2024 | 4.92% | Goldman Sachs | $14 → $16 | Maintains | Buy | |||
05/31/2024 | — | HC Wainwright & Co. | — | Reiterates | → Neutral | |||
05/17/2024 | 44.26% | Craig-Hallum | $15 → $22 | Maintains | Buy | |||
05/15/2024 | — | HC Wainwright & Co. | — | Reiterates | → Neutral | |||
05/13/2024 | — | Raymond James | — | Downgrade | Outperform → Market Perform | |||
05/13/2024 | -8.2% | Goldman Sachs | $10 → $14 | Maintains | Buy | |||
05/13/2024 | 18.03% | Stephens & Co. | $15 → $18 | Maintains | Overweight | |||
05/09/2024 | -1.64% | Craig-Hallum | → $15 | Reiterates | Buy → Buy | |||
05/01/2024 | -1.64% | Craig-Hallum | $12 → $15 | Upgrade | Hold → Buy | |||
04/17/2024 | -1.64% | Stephens & Co. | $15 → $15 | Reiterates | Overweight → Overweight | |||
11/09/2023 | -34.43% | Stephens & Co. | → $10 | Upgrade | Equal-Weight → Overweight | |||
09/26/2023 | -34.43% | Stephens & Co. | → $10 | Reiterates | Equal-Weight → Equal-Weight | |||
08/15/2023 | -21.31% | Raymond James | → $12 | Upgrade | Market Perform → Outperform | |||
08/09/2023 | — | HC Wainwright & Co. | — | Reiterates | → Neutral | |||
07/11/2023 | — | Raymond James | — | Maintains | Market Perform | |||
05/11/2023 | — | BTIG | — | Downgrade | Buy → Neutral | |||
03/07/2023 | -40.98% | Stephens & Co. | $19 → $9 | Downgrade | Overweight → Equal-Weight | |||
03/07/2023 | -14.75% | Goldman Sachs | $25 → $13 | Maintains | Buy | |||
03/03/2023 | -40.98% | Craig-Hallum | $26 → $9 | Downgrade | Buy → Hold | |||
03/03/2023 | 57.38% | Raymond James | → $24 | Downgrade | Strong Buy → Market Perform | |||
02/28/2023 | 63.93% | BTIG | $28 → $25 | Maintains | Buy | |||
02/28/2023 | 24.59% | Stephens & Co. | → $19 | Reiterates | → Overweight | |||
02/28/2023 | 70.49% | Craig-Hallum | $32 → $26 | Maintains | Buy | |||
02/28/2023 | 63.93% | Goldman Sachs | $29 → $25 | Maintains | Buy | |||
02/16/2023 | 24.59% | Stephens & Co. | → $19 | Reiterates | → Overweight | |||
02/06/2023 | 90.16% | Goldman Sachs | $40 → $29 | Maintains | Buy | |||
01/31/2023 | 57.38% | Raymond James | $26 → $24 | Maintains | Strong Buy | |||
11/08/2022 | 70.49% | Raymond James | $35 → $26 | Maintains | Strong Buy | |||
11/07/2022 | 83.61% | BTIG | $37 → $28 | Maintains | Buy | |||
11/04/2022 | 162.3% | Goldman Sachs | $45 → $40 | Maintains | Buy |
El último precio objetivo de CareDx (NASDAQ:CDNA) fue comunicado por BTIG el septiembre 23, 2025. La firma de analistas fijó un precio objetivo para $22.00 que espera CDNA a rise dentro de 12 meses (un posible 44.26% upside). 14 firmas de analistas han reportado calificaciones en el último año.
La última calificación de analistas para CareDx (NASDAQ:CDNA) fue proporcionada por BTIG, y CareDx reiterado su buy calificación.
La última revisión al alza de CareDx Inc se produjo en enero 15, 2025, cuando Wells Fargo elevó su precio objetivo a $24. Wells Fargo anteriormente tenía an underweight para CareDx Inc.
La última revisión a la baja de CareDx Inc se produjo en mayo 13, 2024, cuando Raymond James cambió su precio objetivo de N/A a N/A para CareDx Inc.
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de CareDx, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de CareDx se registró el septiembre 23, 2025, por lo que la próxima calificación estará disponible en torno al septiembre 23, 2026.
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de CareDx (CDNA) fue un reiterado con un precio objetivo de $22.00 a $22.00. El precio actual al que cotiza CareDx (CDNA) es de $15.25, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.